HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gegg, M. E. Articles by Greenwood, J. Search for Related Content PubMed PubMed Citation Articles by Gegg, M. E. Articles by Greenwood, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATORVASTATIN HEPTANOIC ACID LOVASTATIN PYRROLE Medline Plus Health Information Autoimmune Diseases

Suppression of Autoimmune Retinal Disease by Lovastatin Does Not Require Th2 Cytokine Induction¹

Matthew E. Gegg^2,*, Rachel Harry^2,, Deborah Hankey, Hadi Zambarakji, Gareth Pryce, David Baker, Peter Adamson^*, Virginia Calder and John Greenwood^3,*

^* Division of Cellular Therapy, and Division of Clinical Ophthalmology, Institute of Ophthalmology, University College London, Department of Neuroinflammation, Institute of Neurology, University College London, and Vitreoretinal Unit, Moorfields Eye Hospital, London, United Kingdom

Intraocular inflammatory diseases are a common cause of severe visual impairment and blindness. In an acute mouse model of autoimmune retinal disease, we demonstrate that treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, lovastatin, suppresses clinical ocular pathology, retinal vascular leakage, and leukocytic infiltration into the retina. Efficacy was reversed by coadministration of mevalonolactone, the downstream product of 3-hydroxy-3-methylglutaryl coenzyme A reductase, but not by squalene, which is distal to isoprenoid pyrophosphate metabolites within the cholesterol biosynthetic pathway. Lovastatin treatment (20 mg/kg/day i.p.) over 7 days, which resulted in plasma lovastatin hydroxyacid concentrations of 0.098 ± 0.03 µM, did not induce splenocyte Th2 cytokine production but did cause a small reduction in Ag-induced T cell proliferation and a decrease in the production of IFN- and IL-10. Thus, it is possible to dissociate the therapeutic effect of statins in experimental autoimmune uveitic mice from their activity on the Th1/Th2 balance. Statins inhibit isoprenoid pyrophosphate synthesis, precursors required for the prenylation and posttranslational activation of Rho GTPase, a key molecule in the endothelial ICAM-1-mediated pathway that facilitates lymphocyte migration. Consistent with inhibition of leukocyte infiltration in vivo, lovastatin treatment of retinal endothelial cell monolayers in vitro leads to inhibition of lymphocyte transmigration, which may, in part, account for drug efficacy. Unlike lovastatin, atorvastatin treatment showed little efficacy in retinal inflammatory disease despite showing significant clinical benefit in experimental autoimmune encephalomyelitis. These data highlight the potential differential activity of statins in different inflammatory conditions and their possible therapeutic use for the treatment of human posterior uveitis.

This article has been cited by other articles:

				E. Mira, B. Leon, D. F. Barber, S. Jimenez-Baranda, I. Goya, L. Almonacid, G. Marquez, A. Zaballos, C. Martinez-A., J. V. Stein, et al. Statins Induce Regulatory T Cell Recruitment via a CCL1 Dependent Pathway J. Immunol., September 1, 2008; 181(5): 3524 - 3534. [Abstract] [Full Text] [PDF]

				E. C. Jury, D. A. Isenberg, C. Mauri, and M. R. Ehrenstein Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus J. Immunol., November 15, 2006; 177(10): 7416 - 7422. [Abstract] [Full Text] [PDF]

				E Hothersall, C McSharry, and N C Thomson Potential therapeutic role for statins in respiratory disease. Thorax, August 1, 2006; 61(8): 729 - 734. [Abstract] [Full Text] [PDF]

				H. J. Zambarakji, T. Nakazawa, E. Connolly, A. M. Lane, S. Mallemadugula, M. Kaplan, N. Michaud, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2623 - 2631. [Abstract] [Full Text] [PDF]

				M. A. Toscano, A. G. Commodaro, J. M. Ilarregui, G. A. Bianco, A. Liberman, H. M. Serra, J. Hirabayashi, L. V. Rizzo, and G. A. Rabinovich Galectin-1 Suppresses Autoimmune Retinal Disease by Promoting Concomitant Th2- and T Regulatory-Mediated Anti-Inflammatory Responses J. Immunol., May 15, 2006; 176(10): 6323 - 6332. [Abstract] [Full Text] [PDF]

				B. Lozanoska-Ochser, F. Barone, C. Pitzalis, and M. Peakman Atorvastatin Fails to Prevent the Development of Autoimmune Diabetes Despite Inhibition of Pathogenic {beta}-Cell-Specific CD8 T-Cells. Diabetes, April 1, 2006; 55(4): 1004 - 1010. [Abstract] [Full Text] [PDF]

				S. E. Dunn, S. Youssef, M. J. Goldstein, T. Prod'homme, M. S. Weber, S. S. Zamvil, and L. Steinman Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin J. Exp. Med., February 21, 2006; 203(2): 401 - 412. [Abstract] [Full Text] [PDF]